Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
BIVAL trial of bivalirudin infusion versus unfractionated heparin during primary PCI for large STEMI
NL-OMON41679Phase 3Active, not recruiting
- Sponsor
- The Medicines Company
- Start
- Dec 2014
- Modality
- Small Molecules, Recombinant Proteins and Enzymes, Peptides
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial in myocardial infarction (MI) comparing Bivalirudin with Unfractionated heparin (2 arms). Primary endpoint: Infarct size at 5 days. Started Dec 2014; status: active, not recruiting.
02
Drugs
bivalirudinheparin
03
Conditions
myocardial infarction (MI)
Beyond the preview
Go deeper on NL-OMON41679.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON41679.